Heron Therapeutics
HRTX
162 hedge funds and large institutions have $57.2M invested in Heron Therapeutics in 2026 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 40 reducing their positions, and 22 closing their positions.
71% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $914K
45% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 40
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
3% less funds holding
Funds holding: 167 → 162 (-5)
12.58% less ownership
Funds ownership: 83.2% → 70.62% (-13%)
54% less capital invested
Capital invested by funds: $126M → $57.2M (-$68.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$1.89M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$794K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$752K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$731K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$570K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.85M |
| 2 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$4.91M |
| 3 |
Millennium Management
New York
|
-$2.85M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.99M |
| 5 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
-$1.62M |
HRTX Hedge Fund Activity: Q2 2026 in Review
162 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2026, worth a combined $57.2M — down 54% from $126M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of HRTX and 21 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 58 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $1.89M. The largest seller was OrbiMed, exiting entirely with an estimated $7.85M sold.
- 162 institutional investors held Heron Therapeutics (HRTX) as of Q2 2026, down from 167 in Q1 2026.
- Funds reported $57.2M of Heron Therapeutics stock for Q2 2026, down 54% quarter-over-quarter.
- 21 funds opened new Heron Therapeutics positions in Q2 2026 and 22 closed out, a net change of -1 holder.
- The largest Heron Therapeutics buyer in Q2 2026 was Marshall Wace, an estimated $1.89M added.
- The largest Heron Therapeutics seller in Q2 2026 was OrbiMed, an estimated $7.85M sold.
Based on aggregated 13F filings for Q2 2026.